Observational study that will analyse the spread and stratification of lung cancer risk using artificial intelligence - ANASTASIA

Study identifier:D133FR00226

ClinicalTrials.gov identifier:NCT07617636

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

Artificial Intelligence for the Analysis of STAS and lung cancer risk stratification

Medical condition

lung cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

1500

Study type

Observational

Age

50 Years - 80 Years

Date

Study Start Date: 31 Jul 2026
Estimated Primary Completion Date: 31 Aug 2027
Estimated Study Completion Date: 31 Aug 2027

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2026 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria